-
Recent Posts
- December 01 2013 – Human stem cells converted to functional lung cells
- November 30 2013 – Keyhole lung transplant performed on 60-year-old in Chennai
- November 27 2013 – FibroGen Announces Observations of Possible Disease Stabilization and Improvement in Interim Analysis of Phase 2 Study of FG-3019
- November 15 2013 – Enzo Biochem Announces Study in Leading Scientific Journal Linking Idiopathic Pulmonary Fibrosis, a Deadly Human Disease with No Effective Treatment Options, to Presence of a Monkey Virus
- November 10 2013 – Research by Saint Louis University scientists offers way to disrupt fibrosis
Recent Comments
- Fish With Captain Frank on June 20 2012 MicroDose Therapeutx and Moerae Matrix Announce Collaboration to Develop Novel Inhaled Treatment for Idiopathic Pulmonary Fibrosis (IPF)
- Raymond on June 9 2011 – Ascend Trial – Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)
- Johng182 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- Johnf73 on InterMune to Provide Overview of Corporate Strategy, Update on Esbriet Commercialization Plans in the EU and Details of Phase 3 ASCEND Study
- extreme rush on June 28 2012 Grasping at Straws while Gasping for Air
Archives
Categories
Meta
Monthly Archives: September 2011
September 12 2011 InterMune Announces Launch of Esbriet® (pirfenidone) in Germany
BRISBANE, Calif., Sept. 12, 2011 /PRNewswire via COMTEX/ — InterMune, Inc. (NASDAQ: ITMN) today announced that Esbriet® (pirfenidone) will be offered to patients in Germany beginning September 15, 2011. This will mark the first time Esbriet will be commercially available … Continue reading
Posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged Interstitial Lung Disease, IPF, Medical, Medical News, Pulmonary Fibrosis
Leave a comment
September 06 2011 IntelGenx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference in New York
September 06 2011 IntelGenx to Present at the Rodman & Renshaw 13th Annual Healthcare Conference in New York http://www.marketwatch.com/story/intelgenx-to-present-at-the-rodman-renshaw-13th-annual-healthcare-conference-in-new-york-2011-09-06 Drug = INT0024 Testing Information at: http://www.intelgenx.com/_assets/pdf/Intelgenx-FactSheet.pdf
Posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged Interstitial Lung Disease, IPF, Medical, Medical News, Pulmonary Fibrosis
Leave a comment
August 29 2011 Actelion’s Mid-stage Study Of IPF Drug Macitentan Fails To Meet Primary Goal
(RTTNews) – Swiss biopharmaceutical company Actelion Ltd (ALIOF.PK: News ) on Monday said an exploratory phase II study with macitentan in patients with idiopathic pulmonary fibrosis or IPF did not meet its primary endpoint of forced vital capacity. The company … Continue reading
Posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged Interstitial Lung Disease, IPF, Medical, Medical News, Pulmonary Fibrosis
Leave a comment
August 26 2011 Idiopathic Pulmonary Fibrosis (IPF) Therapeutics – Pipeline Assessment and Market Forecasts to 2018
GlobalData valued the global idiopathic pulmonary fibrosis (IPF) therapeutics market at $74.0m in 2010, and is forecast to grow at a compound annual growth rate (CAGR) of 50.2% over the next eight years to reach $1919.9m in 2018. This high … Continue reading
Posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged Interstitial Lung Disease, IPF, Medical, Medical News, Pulmonary Fibrosis
Leave a comment
August 25 2011 Stem cells show promise against respiratory diseases
A study has found that epithelial cells derived from human amnion fluid (hAECs) are therapeutic when transplanted into laboratory mice modelling lung disease. “Respiratory disease is a leading cause of morbidity and mortality,” said corresponding author Dr. Euan M. Wallace, … Continue reading
Posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged Interstitial Lung Disease, IPF, Medical, Medical News, Pulmonary Fibrosis
Leave a comment
August 23 2011 GeNO LLC Receives Federal Grant To Advance Studies of Inhaled Nitric Oxide Product for the Treatment of Chronic Pulmonary Diseases
COCOA, Fla., Aug. 23, 2011 /PRNewswire/ — GeNO LLC, (www.genollc.com) a privately held, advanced development-stage technology company, today announced that it has received a new federal grant to help fund the development of its NITROSYL(TM) (Nitric Oxide for Inhalation) System … Continue reading
Posted in IPF, Medical, Pulmonary Fibrosis, Uncategorized
Tagged Interstitial Lung Disease, IPF, Medical, Medical News, Pulmonary Fibrosis
Leave a comment